ATE420100T1 - Verfahren zur synthese konformationell gehinderter peptide, peptidometika und deren verwendung als synthetische impfstoffe - Google Patents

Verfahren zur synthese konformationell gehinderter peptide, peptidometika und deren verwendung als synthetische impfstoffe

Info

Publication number
ATE420100T1
ATE420100T1 AT04739532T AT04739532T ATE420100T1 AT E420100 T1 ATE420100 T1 AT E420100T1 AT 04739532 T AT04739532 T AT 04739532T AT 04739532 T AT04739532 T AT 04739532T AT E420100 T1 ATE420100 T1 AT E420100T1
Authority
AT
Austria
Prior art keywords
synthesis
relates
peptidometics
link
methods
Prior art date
Application number
AT04739532T
Other languages
English (en)
Inventor
Gerd Pluschke
Ursula Kienzl
John Robinson
Rinaldo Zurbriggen
Original Assignee
Pevion Biotech Ltd
Swiss Tropical Inst
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pevion Biotech Ltd, Swiss Tropical Inst, Univ Zuerich filed Critical Pevion Biotech Ltd
Application granted granted Critical
Publication of ATE420100T1 publication Critical patent/ATE420100T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04739532T 2003-06-02 2004-06-02 Verfahren zur synthese konformationell gehinderter peptide, peptidometika und deren verwendung als synthetische impfstoffe ATE420100T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03012520A EP1484336A1 (de) 2003-06-02 2003-06-02 Methode zur Herstellung von konformationseingeschränkten Peptiden, Peptidomimetika und deren Verwendung als synthetische Vaccine

Publications (1)

Publication Number Publication Date
ATE420100T1 true ATE420100T1 (de) 2009-01-15

Family

ID=33155135

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04739532T ATE420100T1 (de) 2003-06-02 2004-06-02 Verfahren zur synthese konformationell gehinderter peptide, peptidometika und deren verwendung als synthetische impfstoffe

Country Status (9)

Country Link
US (2) US7569541B2 (de)
EP (2) EP1484336A1 (de)
AT (1) ATE420100T1 (de)
AU (1) AU2004242787B9 (de)
CA (1) CA2527795C (de)
DE (1) DE602004018916D1 (de)
DK (1) DK1629002T3 (de)
ES (1) ES2320660T3 (de)
WO (1) WO2004106366A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP2014279A1 (de) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomen enthaltend Haemagglutinin, das von über Zelllinien hergestellten Influenza-Viren stammt, Zusammensetzungen, Herstellungsverfahren, Verwendung davon
WO2011056561A1 (en) * 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
JP6190113B2 (ja) 2010-03-03 2017-08-30 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア オリゴマー特異アミロイドベータエピトープおよび抗体
US10487114B2 (en) * 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
EP2968548B1 (de) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Verfahren und zusammensetzungen zur erzeugung und verwendung konformationsspezifischer antikörper
EP3374381A4 (de) 2015-11-09 2019-05-15 The University Of British Columbia Epitope in der amyloid-beta-mittelregion und konformativ selektive antikörper dazu
DE102016100898B4 (de) * 2016-01-20 2021-08-12 Infineon Technologies Ag Chipkarte und Verfahren zum Ausbilden einer Chipkarte
WO2018232062A1 (en) * 2017-06-15 2018-12-20 University Of Washington Macrocyclic polypeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010935A1 (en) * 1988-05-09 1989-11-16 Abbott Laboratories Atrial peptide derivatives

Also Published As

Publication number Publication date
AU2004242787B2 (en) 2010-05-27
AU2004242787B8 (en) 2010-07-15
CA2527795C (en) 2014-04-22
ES2320660T3 (es) 2009-05-27
DK1629002T3 (da) 2009-04-14
WO2004106366A1 (en) 2004-12-09
EP1484336A1 (de) 2004-12-08
CA2527795A1 (en) 2004-12-09
US7569541B2 (en) 2009-08-04
EP1629002A1 (de) 2006-03-01
US20090324707A1 (en) 2009-12-31
AU2004242787A1 (en) 2004-12-09
US20060258564A1 (en) 2006-11-16
DE602004018916D1 (de) 2009-02-26
US20110008414A9 (en) 2011-01-13
WO2004106366A8 (en) 2005-02-03
AU2004242787B9 (en) 2010-10-14
EP1629002B1 (de) 2009-01-07

Similar Documents

Publication Publication Date Title
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
WO2006031811A3 (en) Glycopegylated interferon alpha
ATE420100T1 (de) Verfahren zur synthese konformationell gehinderter peptide, peptidometika und deren verwendung als synthetische impfstoffe
BRPI0516385A (pt) composições contendo aminoácidos não naturais e polipeptìdeos, métodos envolvendo os mesmos e usos dos mesmos
NO20082716L (no) Sammensetninger og fremgangsmater for fremstilling av en sammensetning
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
WO2006074467A3 (en) Glycopegylated granulocyte colony stimulating factor
RU2009100884A (ru) Пептидные фрагменты для индукции синтеза белков внеклеточного матрикса
EP1801206A4 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
RU2008137796A (ru) Пептиды и производные пептидов, а также содержащие их фармацевтические композиции
MX2009012326A (es) Peptidos de señalizacion.
Ribić et al. Synthesis and Immunostimulating Properties of Novel Adamant‐1‐yl Tripeptides
RU2009102195A (ru) Белок-связывающие производные метотрексата и содержащие их лекарства
DE69115539T2 (de) Immunologische Komponente, Verfahren zur Synthese und Verwendung in Anit-Malaria-Impfstoff-Zusammensetzungen
WO2006014429A3 (en) Cidofovir peptide conjugates as prodrugs
Limal et al. Solid-phase synthesis of N, N′-unsymmetrically substituted ureas: application to the synthesis of carbaza peptides
ATE451384T1 (de) Verfahren zur herstellung von peptiden
US20190309022A1 (en) Novel modulators of melanocortin receptors
ATE350393T1 (de) Synthese und charakterisierung neuer systeme zum hinführen und zur vektorisierung von molekülen von therapeutischem interesse zu targetzellen
KR101224809B1 (ko) 레티노산 유도체, 이의 제조 방법 및 이를 포함하는 화장품 조성물
Stefanowicz et al. Threonine at position 6 is not essential for the immunosuppressive activity of HLA-DQ (β164–172)-hexapeptide
NO994929L (no) Syntetiske peptider, nyttige i biologiske tester, for påvisning av infeksjoner forårsaket av gruppe 0 HIV-1 virus
Ekkati et al. Preparation of N-acetyl, tert-butyl amide derivatives of the 20 natural amino acids
ATE549399T1 (de) Verfahren zur herstellung von pravastatin
WO2025186318A8 (en) Veterinary compositions of modified virus-like particles of cmv and feline il-1beta mutein antigens

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1629002

Country of ref document: EP

EEIH Change in the person of patent owner